Preview

Nephrology and Dialysis

Advanced search

A clinical-morphological analysis of the medicinal kidney lesions during therapy with non-steroid anti-inflammatory drugs

Abstract

The patients of specialized hospitals of the Rostov area have been surveyed to analyse medicinal lesions of kidneys treated with non-steroid anti-inflammatory drugs. At the first stage, anamnesis, clinical features and laboratory parameters were analyzed. At the second stage we analyzed morphological changes in kidney biopsy. At the third stage we developed a forecast system of morphological changes to estimate of the risk of the pathology. 21 patients were surveyed (12 M/9 F). The middle age was 39,5 years. 19 patients (90,5%) had high blood pressure; 8 (38,1%) had edema; 9 (42,9%) had delicacy; 7 ones (33,3%) had nausea; 6 (28,6%) had lumbar pains; 2 (9,5%) had headaches; 4 (19,0%) had the high fever; 10 (47,6%) had polyuria. The duration of the disease varied from 2 months to 22 years. The changes of the laboratory parameters were as follows: 14 people (66,7%) had decreased hemoglobin; 7 (33,3%) had a decrease in erythrocytes; 15 (71,4%) had increased the ESR; 17 (81,0%) had hematuria; 19 (90,5%) had proteinuria; 11 ones (52,4%) had leukocyturia; 11 (52,4%) had decreased urea density in the Zimnitsky test. Changes in urine were found in all patients; 14 patients (61,7%) had renal dysfunction estimated by creatinine level. Morphological changes were found in glomeruli, intersticial tissue, tubules and blood vessels. We have obtained equations which allow one to estimate the risk of the development of pathological changes and developed a system of forecasting the risk of morphological changes due to medicinal kidney lesions treated with non-steroid anti-inflammatory drugs.

About the Authors

M. M. Batjushin
ГОУ ВПО Ростовский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию, г. Ростов-на-Дону
Russian Federation


A. E. Macionis
ГОУ ВПО Ростовский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию, г. Ростов-на-Дону
Russian Federation


O. V. Dmitrieva
ГОУ ВПО Ростовский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию, г. Ростов-на-Дону
Russian Federation


P. E. Povilaite
ГОУ ВПО Ростовский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию, г. Ростов-на-Дону
Russian Federation


V. P. Terent’Ev
ГОУ ВПО Ростовский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию, г. Ростов-на-Дону
Russian Federation


References

1. Залькалн Я.П. Анальгетическая нефропатия (эпидемиологическое, клиническое и морфологическое изучение). Автореф. дис… канд. мед. наук. Рига: 1980. 18 с.

2. Команденко М.С., Шулутко Б.И., Ракитянская И.А., Зусь Б.А. Механизмы развития лекарственной нефропатии. Терапевтический архив, 1989. Т. 61. №6: С. 36-38.

3. Тареева И.Е. Нефрология: руководство. М., 2000. 687 с.

4. Шилов Е., Андросова С. Лекарственные поражения почек. Врач, 2002. № 6. С. 47-49.

5. Шулутко Б.И. Нефрология 2002, современное состояние проблемы. СПб.: Ренкор, 2002. 780 с.

6. Brunner F.P., Selwood N.H. End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortality. Nephrol Dial Transplant, 1994. Vol. 9: Р. 1371-1376.

7. Elseviers M.M., De Broe M.E. Analgesic nephropathy: is it caused by multi-analgesic abuse or single substance use? Drug Saf, 1999. Vol. 20. N. 1. Р. 15-24.

8. Feinstein Alvan R. et al. Relationship between nonphenacetin combined analgesics and nephropathy: A review. Kidney International, 2000. Vol. 58. Р. 2259-2264.

9. Gloor F. Liber verschiedene Formen der Papillennekrose der Nieren. Path Microbiol Basle, 1960. Vol. 23. Р. 262-272.

10. Henrich W.L., Agodoa L.E., Barrett B. et al. National Kidney Foundation Position Paper. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the National Kidney Foundation. Am J Kidney Dis, 1996. Vol. 27. Р. 162-165.

11. Kistler Thomas, Ambiihl Patrice M. Renal safety of combined cyclooxygenase 2 (COX-2) inhibitor and angiotensin II receptor blocker administration in mild volume depletion. Swiss Med Wkly, 2001. Vol. 131. Р. 193-198.

12. Mihatsch M.J., Khanlari B., Brunner Felix P. Obituary to analgesic nephropathy - an autopsy study. Nephrol Dial Transplant, 2006. Vol. 21. Р. 3139-3145.

13. Mihatsch M.J., Zollinger H.U. Analgesic nephropathy. Zentralbl Allg Pathol, 1986. Vol. 132. N. 5-6. Р. 395-411.

14. Morgenstern S.J., Burns F.J., Fraley D.S. Ibuprofen-associated lipid nephrosis without interstitial nephritis. Am J Kidney Dis, 1989. Vol. 16. Р. 50-52.

15. Nanra R.S. Pattern of renal dysfunction in analgesic nephropathy - comparison with glomerulonephritis. Nephrol Dial Transplant, 1992. Vol. 7. 384-389.

16. Schwarz A. Analgesic-associated nephropathy. Klin Wochenschr, 1987. Vol. 65. N. 1. P. 1-16.

17. Schwarz A. Beethoven's renal disease based on his autopsy: a case of papillary necrosis. Am J Kidney Dis, 1993. Vol. 21. N. 6. 643-652.

18. Sedor J.R., Davidson E.W., Dunn M.J. Effects of nonsteroidal anti-inflammatory drugs in healthy subjects. Am J Med, 1986. Vol. 81. 2B. 58-70.

19. Silva Fred G., D’Agati Vivette D., Nadasdy Tibor. Renal Biopsy. New York, Edinburgh, London, Madrid, Melbourne, San Francisco, Tokyo: Churchill Livingstone, 1997. 500 p.

20. Spiihler O., Zollinger H.U. Die chronische interstitielle Nephritis. Z Klin Med, 1953. Vol. 151. 1-50.


Review

For citations:


Batjushin M.M., Macionis A.E., Dmitrieva O.V., Povilaite P.E., Terent’Ev V.P. A clinical-morphological analysis of the medicinal kidney lesions during therapy with non-steroid anti-inflammatory drugs. Nephrology and Dialysis. 2009;11(1):44-49. (In Russ.)

Views: 4


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1680-4422 (Print)
ISSN 2618-9801 (Online)